CG Oncology grants Isabel Kalofonos 92,000 stock options

Twenty-five percent vests after 12 months, with the rest vesting in 36 equal monthly installments over the subsequent three years.

Rhea-AI Filing Summary

CG Oncology, Inc. Chief Commercial Officer Isabel Kalofonos received 92,000 employee stock options on October 15, 2026, with an exercise price of $61.86 per share and an expiration date of October 14, 2036. The options have a four-year vesting period beginning October 13, 2026, subject to continuous service through each vesting date.

Insider Trade Summary

Grant/Award: 92,000 shares

Grant/Award 1 txn

Insider Kalofonos Isabel

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy) F1	92,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 92,000 contracts (Direct)

Footnotes (1)

1. F1. The stock option vests over a four-year period starting on October 13, 2026 (the "Vesting Commencement Date"), with 25% of the shares vesting on the date that is twelve months after the Vesting Commencement Date and the remainder vesting in thirty-six equal monthly installments over the subsequent three-year period, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Key Figures

Employee stock options awarded: 92,000 options Exercise price: $61.86 per share Expiration date: October 14, 2036 +3 more

6 metrics

Employee stock options awarded 92,000 options Awarded October 15, 2026; underlying security is common stock

Exercise price $61.86 per share For the employee stock options

Expiration date October 14, 2036 Employee stock options

Vesting period Four years Begins October 13, 2026; subject to continuous service through each vesting date

Initial vesting tranche 25% of the shares Vests on the date that is 12 months after October 13, 2026

Remaining vesting installments 36 equal monthly installments Over the subsequent three-year period

Key Terms

Employee Stock Option (right to buy), Vesting Commencement Date, exercise price

3 terms

Employee Stock Option (right to buy) financial

"Employee Stock Option (right to buy)"

Vesting Commencement Date financial

"the "Vesting Commencement Date""

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

exercise price financial

"conversion_or_exercise_price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are Isabel Kalofonos's CGON stock option award terms?

Isabel Kalofonos received 92,000 employee stock options on October 15, 2026. The exercise price is $61.86 per share, and the options expire October 14, 2036.

How do Isabel Kalofonos's CGON options vest?

Twenty-five percent of the shares vest on the date that is 12 months after October 13, 2026. The remainder vests in 36 equal monthly installments over the subsequent three years, subject to her continuous service through each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/19/2026 - 04:30 PM EDT Accepted by SEC EDGAR 10/19/2026 - 04:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kalofonos Isabel

(Last) (First) (Middle)

C/O CG ONCOLOGY, INC.

3000 PEGASUS PARK DRIVE, SUITE 1640

(Street)

DALLAS TEXAS 75247

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CG Oncology, Inc. [ CGON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$61.86	10/15/2026		A		92,000		(1)	10/14/2036	Common Stock	92,000	$0	92,000	D

Explanation of Responses:

1. The stock option vests over a four-year period starting on October 13, 2026 (the "Vesting Commencement Date"), with 25% of the shares vesting on the date that is twelve months after the Vesting Commencement Date and the remainder vesting in thirty-six equal monthly installments over the subsequent three-year period, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

	/s/ Joshua F. Patterson, Attorney-in-Fact for Isabel Kalofonos	10/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)